SCHEMBL3129354

SCHEMBL3129354

COc1ccc(N(Cc2c(F)cccc2F)c2cccc(C(=O)O)c2)cc1OC(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.43
RXRB P28702 1/20 0.43
RXRG P48443 1/20 0.43
LMNA P02545 2/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
MEP1B Q16820 3/20 0.41
MRGPRX4 Q96LA9 3/20 0.41
PDE4B Q07343 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PPARA Q07869 1/20 0.39
MAPK14 Q16539 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3129190 0.92 LMNA (0.47) LMNAMAPK1HTTRAB9AMEP1B
SCHEMBL3129663 0.88 HTT (0.41) LMNAMAPK1HTTRAB9AMEP1B
SCHEMBL3215514 0.88 PDE4B (0.38) RXRARXRBRXRGLMNAPDE4B
SCHEMBL3126269 0.87 TSHR (0.48) LMNAMAPK1HTTRAB9AMEP1B
SCHEMBL3123513 0.86 PDE4D (0.47) RXRARXRBRXRGMRGPRX4PDE4B
SCHEMBL3121009 0.85 PDE4A (0.42) RXRARXRBRXRGMEP1BMRGPRX4
SCHEMBL4202300 0.82 PDE4B (0.60) PDE4BPDE4APDE4CPDE4D
SCHEMBL3123339 0.82 PDE4B (0.58) PDE4BPDE4APDE4CPDE4D
SCHEMBL3133069 0.82 RXRA (0.42) RXRARXRBRXRGMEP1BMRGPRX4
SCHEMBL2908126 0.81 MRGPRX4 (0.42) LMNAMAPK1HTTRAB9AMEP1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B RXRA 2856/4885RXRB 2676/4885RXRG 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.